{"id":136451,"date":"2024-10-15T16:00:09","date_gmt":"2024-10-15T08:00:09","guid":{"rendered":"https:\/\/www.curtin.edu.au\/research\/?page_id=136451"},"modified":"2024-10-15T16:00:10","modified_gmt":"2024-10-15T08:00:10","slug":"aslam-anis","status":"publish","type":"page","link":"https:\/\/www.curtin.edu.au\/research\/research-rumble\/aslam-anis\/","title":{"rendered":"Is big pharma guiding federal drug policy? Impact of proposed regulations on prices & access to new medicines"},"content":{"rendered":"\n
<\/div>\n\n\n\n

Event details<\/strong><\/h3>\n\n\n\n
\n
\n

Join us for an intriguing discussion led by Professor Aslam Anis from the University of British Columbia on the influence of big pharmaceutical companies on federal drug policy. Are decisions being made in the interest of public health or profit margins?<\/p>\n\n\n\n

–<\/p>\n\n\n\n

In February 2023, Dr. Matthew Herder resigned from the Patented Medicine Prices Review Board (PMPRB), citing the government\u2019s failure to implement critical reforms to lower medicine costs. Health Minister Jean-Yves Duclos has denied any interference, stressing that the PMPRB is politically independent.<\/p>\n\n\n\n

Dr Anis will explore this impasse, the role of the PMPRB in drug pricing, and the future of pharmaceutical regulation in Canada.
<\/p>\n<\/div>\n\n\n\n

\n\n \n
\n\n \n \n

Date
\n<\/strong>Monday 11 November 2024<\/p>\n

Time<\/strong>
\n2.00pm \u2013 3.30pm <\/p>\n

Location <\/strong>
\nBankwest Lecture Theatre<\/a>
\nB200A.220
\nCurtin University<\/p>\n<\/div>\n \n \n <\/div>\n\n<\/mimas-block>\n\n\n\n \n \n

\n\n

Button block<\/h2>\n \n \n \n \n <\/div>\n\n Register now<\/a>\n <\/mimas-block><\/div>\n<\/div>\n\n\n\n

Presenter<\/strong><\/h3>\n\n\n\n\n \n\n
\n
\"Dr<\/div>
\n Main Speaker\n <\/div>

Dr Aslam Anis<\/h2><\/div>
\n University of British Columbia\n <\/div>

Dr Aslam Anis is Professor and Director at the University of British Columbia, School of Population and Public Health. His research area spans across cost effectiveness of AIDS treatments, drug assessments – pharmacoeconomics, health care economics, health regulations, Health economics, rheumatoid arthritis, biologic therapies.<\/p>

Dr Anis is one of Canada\u2019s most distinguished health economists. In a career spanning more than 25 years, he has achieved international recognition for his seminal contributions to the fields of pharmacoeconomics, pharmaceutical industry regulation, and drug pricing. His current and past work is influential across a broad spectrum of health research domains including HIV\/AIDS, rheumatoid arthritis, substance use and addiction treatment, among others. He has published over 200 peer-reviewed manuscripts and regularly presents at national and international conferences as an expert in his field.<\/p>

Dr Anis has also developed a reputation for leadership and administrative excellence. He is a key architect for the continuing success of the Canadian HIV Trials Network and the Centre for Advancing Health Outcomes, where he has made remarkable contributions to the health sciences and further established himself as one of the pre-eminent health economists in Canada and internationally.<\/p><\/div><\/div><\/div> <\/div>\n\n \n<\/mimas-block>\n\n\n\n\n \n

\n\n

Contact us<\/h2>\n \n \n

To find out more about this event, contact the Faculty of Health.<\/p>\n<\/div>\n \n \n

\n Get in touch\n